| Identification | Back Directory | [Name]
Bleomycin A5 | [CAS]
11116-32-8 | [Synonyms]
Nsc350895
bleomycetin
Bleomycin A5
Pingyangmycin A5
Zhengguanmycin A5
Bleomycin A5 USP/EP/BP
N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide
Bleomycinamide, N1-[3-[(4-aminobutyl)amino]propyl]- | [EINECS(EC#)]
234-357-0 | [Molecular Formula]
C57H89N19O21S2 | [MOL File]
11116-32-8.mol | [Molecular Weight]
1440.56 |
| Chemical Properties | Back Directory | [density ]
1.1028 (rough estimate) | [refractive index ]
1.6700 (estimate) | [form ]
Solid | [pka]
10.84±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bleomycin A5 (Pingyangmycin) is an orally active glycopeptide antibiotics. Bleomycin A5 has a role as an antineoplastic agent, an apoptosis inducer and a bacterial metabolite[1][2]. | [Definition]
ChEBI: A member of the class of bleomycins that is used in sclerotherapy for cervicofacial lymphatic malformations. | [in vivo]
Bleomycin A5 (Pingyangmycin) (oral; 18 daily doses of 5 mg/kg) occurs anorexia, cachexia, skin ulcerations, and death and observes interstitial pneumonia, nephrosis and focal necrosis of the adrenal cortex[1]. | [References]
[1] Yaowu Yang, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011 Jan;53(1):150-5. DOI:10.1016/j.jvs.2010.07.019
[2] Lin Fu-Tian, et al. Antitumor activity and preclinical pharmacological study of pingyangmycin. Zhonghua Zhongliu Zazhi. Volume: 1. Issue: 3. Pages: 161-6. Journal; English Abstract; Article. 1979. |
|
|